Efficacy of bevacizumab combined with neoadjuvant chemotherapy in the treatment of advanced ovarian cancer
ZHANG Yan
WANG Shuhua
WANG Huiling
CHEN Ruixiang
JIANG Shan
YANG Shenghua
YANG Jun
Abstract：Objective To investigate the clinical efficacy and safety of bevacizumab combined with neoad-juvant chemotherapy in the treatment of advanced ovarian cancer.Methods In this prospective study,92 patients with advanced ovarian cancer treated at the First Affiliated Hospital of Xinxiang Medical University from May 2020 to May 2023 were randomly assigned to the bevacizumab group(n=46,receiving bevacizumab plus paclitaxel and carboplatin chemotherapy)and the paclitaxel group(n=46,receiving paclitaxel and carboplatin chemotherapy)according to the ran-dom number table method.The therapeutic efficacy,changes in serum tumor marker cancer antigen 125(CA125),and the incidence of adverse reactions were compared between the bevacizumab group and the paclitaxel group after 3 cycles of treatment.The Kaplan-Meier analysis was used to analyze the prognosis of of patients in the bevacizumab group and the paclitaxel group.Results The total effective rate was 58.70％(27/46)and the disease control rate was 89.13％(41/46)in the bevacizumab group,higher than those in the paclitaxel group(36.96％(17/46)and 69.57％(32/46),respectively),and the differences were statistically significant(x2=4.356 and 5.373,both P＜0.05).After treatment,the reduction in se-rum CA125 levels in the bevacizumab group(309.56±43.12)U/mL was greater than that in the paclitaxel group(291.36±40.92)U/mL,and the difference was statistically significant(t=4.209,P＜0.05).There was no statistically significant difference in the incidence of gastrointestinal reactions,anemia,proteinuria,bone marrow suppression,hypertension,and bleeding between the two groups(P＞0.05).Among the patients who underwent interval debulking surgery,the R0 resection rate in the bevacizum-ab group was 79.41％(27/34),higher than 53.57％(15/28)in the paclitaxel group,and the difference was statistically significant(x2=4.692,P＜0.05).Kaplan-Meier analysis showed that the 2-year overall survival rate in the bevacizumab group(84.2％,95％CI:73.4％to 95.0％)was significantly higher than that in the paclitaxel group(64.7％,95％CI:50.8％to 78.6％),with a statisti-cally significant difference(Log Rankx2=4.994,P＜0.05).Conclusion Compared with neoadjuvant chemotherapy alone,bev-acizumab combined with neoadjuvant chemotherapy demonstrates superior efficacy in patients with advanced ovarian cancer.It effectively reduces tumor marker levels,prolongs overall survival,and has a controllable safety profile.
Keywords：bevacizumabneoadjuvant chemotherapyovarian cancerefficacysafetytumor marker
Publication Date：2026-01-25
Online Publishing Date：2026-03-03(First online date of this platform, not the publication date of the document)
Pages：6( 16-21 )